An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail
Open Access
- 21 January 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral antiretroviral drug, into monomeric and homodimeric ester prodrugs. The homodimeric prodrug nanosuspension, NMXBIC, shows sustained plasma BIC levels > 16 times the protein-adjusted 95% inhibitory concentration (PA-IC95) for six months after a single injection in Sprague Dawley rats. The results paralleled a short PK tail with the potential for late dose forgiveness. The monomeric prodrug nanosuspension, NM2BIC, shows lower year-long plasma BIC concentrations above PA-IC95 after a single injection. After repeated injections, NMXBIC and NM2BIC are well tolerated in New Zealand White rabbits. NMXBIC’s physicochemical properties and high BIC loading/unit mass of the prodrug contribute to its unique ULA PK profile. These results support its development as a ULA formulation for HIV-1 treatment and prevention.Keywords
All Related Versions
Funding Information
- Division of Intramural Research (R01AI145542, R01AI158160 and R01AI163042)
This publication has 45 references indexed in Scilit:
- Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?Current HIV/AIDS Reports, 2022
- Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and RilpivirineClinical Pharmacokinetics, 2021
- Design and Testing of a Cabotegravir Implant for HIV PreventionJournal of Controlled Release, 2020
- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profilesBiomaterials, 2018
- The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspensionJournal of Controlled Release, 2016
- Intramuscular Administration of Paliperidone Palmitate Extended-Release Injectable Microsuspension Induces a Subclinical Inflammatory Reaction Modulating the Pharmacokinetics in RatsJournal of Pharmaceutical Sciences, 2014
- Solvent induced phase inversion-based in situ forming controlled release drug delivery implantsJournal of Controlled Release, 2014
- Cholesterol: Factors Determining Blood Levels2013
- Foreign body reaction to biomaterialsSeminars in Immunology, 2008
- Biocompatibility studies of naltrexone sustained release formulationsJournal of Controlled Release, 1992